Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of mycobacterium tuberculosis inha

Journal of Medicinal Chemistry

Volumn 57, Issue 4, 2014, Pages 1276-1288

  Encinas, Lourdes ^b   O'Keefe, Heather ^a   Neu, Margarete ^c   Remuiñán, Modesto J ^b   Patel, Amish M ^a   Guardia, Ana ^b   Davie, Christopher P ^a   Pérez Macías, Natalia ^d   Yang, Hongfang ^a   Convery, Maire A ^c   Messer, Jeff A ^a   Pérez Herrán, Esther ^b   Centrella, Paolo A ^e   Álvarez Gómez, Daniel ^b   Clark, Matthew A ^e   Huss, Sophie ^b   O'Donovan, Gary K ^a   Ortega Muro, Fátima ^b   McDowell, William ^c   Castañeda, Pablo ^b   Arico Muendel, Christopher C ^a   Pajk, Stane ^f   Rullás, Joaquín ^b   Angulo Barturen, Iñigo ^b   Álvarez Ruíz, Emilio ^b   Mendoza Losana, Alfonso ^b   Ballell Pages, Lluís ^b   Castro Pichel, Julia ^b   Evindar, Ghotas ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (Spain)

^c GLAXOSMITHKLINE   (United Kingdom)

^d INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^e X Chem Incorporated   (United States)

^f UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; KATG PROTEIN; LEAD; N ((3R,5S) 1 (BENZOFURAN 3 CARBONYL) 5 (ETHYLCARBAMOYL)PYRROLIDIN 3 YL) 3 ETHYL 1 METHYL 1H PYRAZOLE 5 CARBOXAMIDE; N ((3R,5S) 1 (BENZOFURAN 3 CARBONYL) 5 CARBAMOYLPYRROLIDIN 3 YL) 1,3 DIETHYL 1H PYRAZOLE 5 CARBOXAMIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENCODED LIBRARY TECHNOLOGY; ENZYME INHIBITION; FEMALE; HUMAN; IN VIVO STUDY; LUNG TUBERCULOSIS; MOLECULAR LIBRARY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROCESS OPTIMIZATION; STRUCTURE ACTIVITY RELATION;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG DISCOVERY; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84896848906     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401326j     Document Type: Article

References (48)

1. World Health Organisation. Tuberculosis. http://www.who.int/mediacentre/ factsheets/fs104/en/index.html (accessed February 11, 2013).
2. Becerra, M. C.; Bayona, J.; Freeman, J.; Farmer, P. E.; Kim, J. Y. Redefining MDR-TB transmissionhot spots' counterpoint Int. J. Tuberc. Lung Dis. 2000, 4, 387-394
3. Dye, C.; Espinal, M. A.; Watt, C. J.; Mbiaga, C.; Williams, B. G. Worldwide incidence of multidrug-resistant tuberculosis J. Infect. Dis. 2002, 185, 1197-1202
4. Espinal, M. A. The global situation of MDR-TB Tuberculosis (Edinburgh) 2003, 83, 44-51
5. Wright, A.; Zignol, M.; Van Deun, A.; Falzon, D.; Gerdes, S. R.; Feldman, K.; Hoffner, S.; Drobniewski, F.; Barrera, L.; van Soolingen, D.; Boulabhal, F.; Paramasivan, C. N.; Kam, K. M.; Mitarai, S.; Nunn, P.; Raviglione, M. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance Lancet 2009, 373, 1861-1873
6. Chiang, C. Y.; Centis, R.; Migliori, G. B. Drug-resistant tuberculosis: past, present, future Respirology 2010, 15, 413-432
7. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response (WHO/HTM/TB/2010.3). World Health Organization: Geneva, 2010.
8. Shah, N. S.; Wright, A.; Bai, G. H.; Barrera, L.; Boulahbal, F.; Martin-Casabona, N.; Drobniewski, F.; Gilpin, C.; Havelkova, M.; Lepe, R.; Lumb, R.; Metchock, B.; Portaels, F.; Rodrigues, M. F.; Rüsch-Gerdes, S.; Van Deun, A.; Vincent, V.; Laserson, K.; Wells, C.; Cegielski, J. P. Worldwide emergence of extensively drug-resistant tuberculosis Emerging Infect. Dis. 2007, 13, 380-387
9. Berry, M.; Kon, O. M. Multidrug- and extensively drug-resistant tuberculosis: an emerging threat Eur. Respir. Rev. 2009, 18, 195-197
10. What Is DOTS? A Guide to Understanding the WHO Recommended TB Control Strategy Known as DOTS. Document WHO/CDS/CPC/TB/99.270; World Health Organization: Geneva, 1999.
11. Quemard, A.; Sacchettini, J. C.; Dessen, A.; Vilchèze, C.; Bittman, R.; Jacobs, W. R.; Blanchard, J. S. Enzymic characterization of the target for isoniazid in Mycobacterium tuberculosis Biochemistry 1995, 34, 8235-8241
12. Vilcheze, C.; Morbidoni, H. R.; Weisbrod, T. R.; Iwamoto, H.; Kuo, M.; Sacchettini, J. C.; Jacobs, W. R., Jr. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis J. Bacteriol. 2000, 182, 4059-4067
13. Banerjee, A.; Dubnau, E.; Quemard, A.; Balasubramanian, V.; Um, K. S.; Wilson, T.; Collins, D.; de Lisle, G.; Jacobs, W. R., Jr. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis Science 1994, 263, 227-230
14. Dessen, A.; Quemard, A.; Blanchard, J. S.; Jacobs, W. R., Jr.; Sacchettini, J. C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis Science 1995, 267, 1638-1641
15. Parikh, S. L.; Xiao, G.; Tonge, P. J. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid Biochemistry 2000, 39, 7645-7650
16. Scior, T.; Garces-Eisele, S. J. Isoniazid is not a lead compound for its pyridyl ring derivatives, isonicotinoyl amides, hydrazides, and hydrazones: a critical review Curr. Med. Chem. 2006, 13, 2205-2219
17. Argyrou, A.; Vetting, M. W.; Aladegbami, B.; Blanchard, J. S. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid Nat. Struct. Mol. Biol. 2006, 13, 408-413
18. Schroeder, E. K.; de Souza, O. N.; Santos, D. S.; Blanchard, J. S.; Basso, L. A. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis Curr. Pharm. Biotechnol. 2002, 3, 197-225
19. Basso, L. A.; Santos, D. S. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis-an update Med. Chem. Rev. 2005, 2, 393-413
20. Hazbón, M. H.; Brimacombe, M.; Bobadilla Del Valle, M.; Cavatore, M.; Guerrero, M. I.; Varma-Basil, M.; Billman-Jacobe, H.; Lavender, C.; Fyfe, J.; Garcia-Garcia, L.; Leon, C. I.; Bose, M.; Chaves, F.; Murray, M.; Eisenach, K. D.; Sifuentes-Osornio, J.; Cave, M. D.; Ponce de Leon, A.; Alland, D. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2006, 50, 2640-2649
21. Kuo, M. R.; Morbidoni, H. R.; Alland, D.; Sneddon, S. F.; Gourlie, B. B.; Staveski, M. M.; Leonard, M.; Gregory, J. S.; Janjigian, A. D.; Yee, C.; Musser, J. M.; Kreiswirth, B.; Iwamoto, H.; Perozzo, R.; Jacobs, W. R.; Sacchettini, J. C.; Fidock, D. A. Targeting tuberculosis and malaria through inhibition of enoyl reductase compound activity and structural data J. Biol. Chem. 2003, 278, 20851-20859
22. Lu, X. Y.; You, Q. D.; Chen, Y. D. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis Mini-Rev. Med. Chem. 2010, 10, 182-193
23. Ballell Pages, L.; Castro Pichel, J.; Fernandez Menendez, R.; Fernandez Velando, E. P.; Gonzalez del Valle, S.; Leon Diaz, M. L.; Mendoza Losana, A.; Wolfendale, M. J. (Pyrazol-3-yl)-1,3,4-thiadiazole-2-amine and (Pyrazol-3-yl)-1,3,4-thiazol-2-amine Compounds. WO/2010/118852, 2010.
24. Pan, P.; Tonge, P. J. Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds Curr. Top. Med. Chem. 2012, 12, 672-693
25. Castro Pichel, J.; Fernandez Menendez, R.; Fernandez Velando, E. P.; Gonzalez del Valle, S.; Mallo-Rubio, A. 3-Amino-pyrazole Derivatives Useful against Tuberculosis. WO/2012/049161, 2012.
26. Horlacher, O. P.; Hartkoorn, R. C.; Cole, S. T.; Altmann, K.-H. Synthesis and antimycobacterial activity of 2,1′-dihydropyridomycins ACS Med. Chem. Lett. 2013, 4, 264-268
27. Clark, M. A.; Acharya, R. A.; Arico-Muendel, C. C.; Belyanskaya, S. L.; Benjamin, D. R.; Carlson, N. R.; Centrella, P. A.; Chiu, C. H.; Creaser, S. P.; Cuozzo, J. W.; Davie, C. P.; Ding, Y.; Franklin, G. J.; Franzen, K. D.; Gefter, M. L.; Hale, S. P.; Hansen, N. J. V.; Israel, D. I.; Jiang, J.; Kavarana, M. J.; Kelley, M. S.; Kollmann, C. S.; Li, F.; Lind, K.; Mataruse, S.; Medeiros, P. F.; Messer, J. A.; Myers, P.; O'Keefe, H.; Oliff, M. C.; Rise, C. E.; Satz, A. L.; Skinner, S. R.; Svendsen, J. L.; Tang, L.; Vloten, K. V.; Wagner, R. W.; Yao, G.; Zhao, B.; Morgan, B. A. Design, synthesis and selection of DNA-encoded small-molecule libraries Nat. Chem. Biol. 2009, 5, 647-654
28. Deng, H.; O'Keefe, H.; Davie, C. P.; Lind, K. E.; Acharya, R. A.; Franklin, G. J.; Larkin, J.; Matico, R.; Neeb, M.; Thompson, M. M.; Lohr, T.; Gross, J. W.; Centrella, P. A.; O'Donovan, G. K.; Bedard, K. L.; Vloten, K.-v.; Mataruse, S.; Skinner, S. R.; Belyanskaya, S. L.; Carpenter, T. Y.; Shearer, T. W.; Clark, M. A.; Cuozzo, J. W.; Arico-Muendel, C. C.; Morgan, B. A. Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT) J. Med. Chem. 2012, 55, 7061-7079
29. Disch, J. S.; Evindar, G.; Chiu, C. H.; Blum, C. A.; Dai, H.; Jin, L.; Schuman, E.; Lind, K. E.; Belyanskaya, S. L.; Deng, J.; Coppo, F.; Aquilani, L.; Graybill, T. L.; Cuozzo, J. W.; Lavu, S.; Mao, C.; Vlasuk, G. P.; Perni, R. B. Discovery of thieno[3,2- d ]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3 J. Med. Chem. 2013, 56, 3666-3679
30. Graybill, T. L.; King, B. W.; Fosbenner, D. T.; Keller, P. M.; Morgan, B. A.; Clark, M. A.; Cuozzo, J. DNA-Encoded Libraries: A New Resource for Innovative Hit Identification. Abstract of Papers, 237th National Meeting of the American Chemical Society, Salt Lake City, UT, U.S., March 22-26, 2009; American Chemical Society: Washington, DC, 2009; MEDI-297.
31. Evindar, G.; Acharya, R. A.; Arico-Muendel, C. C.; Belyanskaya, S. L.; Brown, J.; Clark, A. M.; Centrella, P. A.; Cuozzo, J. W.; Davie, C. P.; Ding, Y.; Franklin, G. J.; Jeffrey, W.; Gross, J. W.; Israel, D. I.; Jolivette, L. J.; Jurewicz, A. J.; Lakdawala, A. S.; Li, F.; Li, H.; Lind, K. E.; Joseph, P.; Marino, J. P.; Morgan, B. A. Application of Encoded Library Technology (ELT) to the Discovery of Soluble Epoxide Hydrolase Inhibitors. Abstracts of Papers, 238th National Meeting of the American Chemical Society, Washington, DC, United States, August 16-20, 2009; MEDI-2.
32. Davie, C. P.; Centrella, P. A.; O'Donovan, G. K.; Evindar, G.; O'Keefe, H.; Patel, A. M.; Clark, M. A. Design and Synthesis of a Sixteen Million Member DNA-Encoded Library (DEL) and Discovery of Potent Mycobacterium tuberculosis (Mtb) InhA Inhibitors. Abstracts of Papers, 240th National Meeting of the American Chemical Society, Boston, MA, United States, August 22-26, 2010; American Chemical Society: Washington, DC, 2010; MEDI-150.
33. Ding, Y.; O'Keefe, H.; Svendsen, J. L.; Franklin, G. J.; Centrella, P. A.; Clark, M. A.; Acharya, R. A.; Li, F.; Messer, J. A.; Chiu, C. H.; Matico, R. E.; Murray-Thompson, M. F.; Cuozzo, J. W.; Israel, D. I.; Arico-Muendel, C.; Morgan, B. A. Discovery of Potent and Selective Inhibitors for ADAMTS-4 through Encoded Library Technology (ELT). Abstracts of Papers, 240th National Meeting of the American Chemical Society, Boston, MA, United States, August 22-26, 2010; American Chemical Society: Washington, DC, 2010; MEDI-460.
34. Gentile, G.; Merlo, G.; Pozzan, A.; Bernasconi, G.; Bax, B.; Bamborough, P.; Bridges, A.; Carter, P.; Neu, M.; Yao, G.; Brough, C.; Cutler, G.; Coffin, A.; Belyanskaya, S. 5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 1989-1994
35. Mendoza-Losana, A. Gordon Research Conference: Tuberculosis, 2011, (personal communication).
36. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44, 235-249
37. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
38. Lennernas, H.; Abrahamsson, B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension J. Pharm. Pharmacol. 2005, 57, 273-285
39. Dahan, A.; Miller, J. M.; Amidon, G. L. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs AAPS J. 2009, 11, 740-746
40. + and a C16 fatty acyl substrate J. Biol. Chem. 1999, 274, 15582-15589
41. Cantaloube, S.; Veyron-Churlet, R.; Haddache, N.; Daffé, M.; Zerbib, D. The Mycobacterium tuberculosis FAS-II dehydratases and methyltransferases define the specificity of the mycolic acid elongation complexes PLoS One 2011, 6, e29564
42. Koitka, M.; Hochel, J.; Gieschen, H.; Borchert, H. H. Improving the ex vivo stability of drug ester compounds in rat and dog serum: inhibition of the specific esterases and implications on their identity J. Pharm. Biomed. Anal. 2010, 51, 664-678
43. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
44. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
45. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002
46. Carr, R. A. E.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-based lead discovery: leads by design Drug Discovery Today 2005, 10, 987-992
47. Mortenson, P. N.; Murray, C. W. Assessing the lipophilicity of fragments and early hits J. Comput.-Aided Mol. Des. 2011, 25, 663-667
48. Rullas, J.; Garcia, J. I.; Beltran, M.; Cardona, P. J.; Cáceres, N.; García-Bustos, J. F.; Angulo-Barturen, I. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis Antimicrob. Agents Chemother. 2010, 54, 2262-2264